펜형 및 주입기형 약물전달 디바이스 시장 규모, 점유율과 동향 분석 보고서 : 제품별, 치료 용도별, 최종 용도별, 지역별, 부문 예측(2026-2033년)

Pen And Injector Drug Delivery Devices Market Size, Share & Trends Analysis Report By Product (Injectors, Pen), By Therapeutic Use (Autoimmune Disorders, Hormonal Disorders), By End-use, By Region, And Segment Forecasts, 2026 - 2033

US $ 5,950 ￦ 8,981,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 10,491,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 13,510,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

펜형 및 주입기형 약물전달 디바이스 시장 요약

세계의 펜형 및 인젝터형 약제 투여 장비 시장 규모는 2025년에 1,146억 7,000만 달러로 추정되며, 2033년까지 2,365억 4,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 9.6%의 성장률을 보일 것으로 예측됩니다. 이러한 견고한 성장은 의료 현장 전반에서 효과적이고 사용하기 쉬운 첨단 약물 투여 솔루션에 대한 수요가 증가하고 있기 때문입니다.

주요 촉진요인으로는 당뇨병, 암, 자가면역질환 등 잦은 주사가 필요한 만성질환의 유병률 증가, 자동주사기, 펜형 주사기 등 사용이 편리한 주사 툴의 보급 확대, 안전성, 정확성, 환자 편의성을 향상시키는 지속적인 기술 발전 등을 꼽을 수 있습니다. 또한 생물제제 개발 확대, 재택의료로의 전환, 병원 방문 횟수 감소에 대한 집중 강화는 시장 성장을 더욱 촉진하고 있습니다.

펜형 및 인젝터형 약물전달 장치 시장을 주도하는 주요 요인 중 하나는 만성질환 증가 추세와 고령 인구의 급속한 증가입니다. 당뇨병, 암, 심혈관질환, 자가면역질환 등의 만성질환은 신속하고 효과적인 치료 효과를 얻기 위해 주사를 통한 정기적 또는 장기적인 약물 투여가 필요한 경우가 많습니다. 국제당뇨병연맹(IDF)의 2021년 보고서에 따르면 전 세계에서 약 5억 3,700만 명이 당뇨병을 앓고 있으며, 이는 약 10명 중 1명이 당뇨병을 앓고 있다는 것을 의미합니다. 이 숫자는 2045년까지 7억 8,300만 명에 달할 것으로 예측되며, 급격한 증가가 예상됩니다. 이러한 질병이 전 세계에서 증가함에 따라 신뢰할 수 있고 사용하기 쉬운 주사기 장치에 대한 수요는 계속 증가하고 있습니다. 또한 고령화 사회에서는 여러 가지 건강 문제에 직면하는 경우가 많아 주사제를 포함한 잦은 의료 처치가 필요한 경향이 있습니다. 유엔 경제사회국 인구부의 최신 추계 및 예측에 따르면 60세 이상 인구는 2050년까지 15억 명에 달하고, 전 세계 인구의 약 6명 중 1명을 차지할 것으로 예측됩니다. 이러한 인구 구조의 변화는 임상 현장과 가정 간호를 모두 지원하는 편리하고 안전하며 정밀한 투약 시스템의 필요성을 높이고 있으며, 시장 성장에 큰 기여를 하고 있습니다.

약물전달 시스템의 기술 발전은 펜형 및 인젝터형 약물전달 장치의 성장을 주도하고 있습니다. 혁신으로 인해 주사기는 더욱 안전하고 효율적이며, 환자들에게 더 쉽게 사용할 수 있게 되었습니다. 디지털 모니터링 기능을 갖춘 스마트 자동 주사기, 바늘 없는 주사 기술, 개선된 안전 메커니즘 등의 특징은 정확한 투약량을 보장하고 바늘로 인한 부상 위험을 줄이는 데 도움이 됩니다. 재료와 장치 설계의 발전은 또한 편안함을 높이고 집에서 스스로 사용할 수 있도록 도와줍니다. 이는 만성질환을 관리하는 사람들에게 점점 더 중요해지고 있습니다. 예를 들어 2024년 10월 BD와 Ypsomed는 전략적 제휴를 발표하고 BD의 'Neopak XtraFlow' 유리 프리필드 주사기(8mm의 짧은 바늘과 얇은 벽의 캐뉼라를 채택)를 Ypsomed의 'YpsoMate 2.25' 자동주사기에 통합했습니다. 이 디자인은 고점도 생물제제를 집에서 자가 주사하는 환자의 투여를 용이하게 하며, 2단 주사기는 그립력이나 시력에 제한이 있는 사용자를 위해 특별히 고안되었습니다.

이러한 기술적 개선은 채택을 촉진하고, 시장의 큰 성장을 지원할 것입니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 펜형 및 주입기형 약물전달 디바이스 시장 변수와 동향 시장 계보 전망

제4장 펜형 및 주입기형 약물전달 디바이스 시장 : 제품 분석

제5장 펜형 및 주입기형 약물전달 디바이스 시장 : 치료 용도별 추정·동향 분석

제6장 펜형 및 주입기형 약물전달 디바이스 시장 : 최종 용도별 분석

제7장 펜형 및 주입기형 약물전달 디바이스 시장 : 지역별 추정·동향 분석

제8장 펜형 및 주입기형 약물전달 디바이스 시장 : 경쟁 분석

KSA

영문 목차

영문목차

Pen And Injector Drug Delivery Devices Market Summary

The global pen and injector drug delivery devices market size was estimated at USD 114.67 billion in 2025 and is projected to reach USD 236.54 billion by 2033, growing at a CAGR of 9.6% from 2026 to 2033. This strong growth is driven by the rising demand for advanced, effective, and user-friendly drug delivery solutions across healthcare settings..

Key drivers include the increasing prevalence of chronic conditions such as diabetes, cancer, and autoimmune disorders that require frequent injections; growing adoption of user-friendly injection tools such as autoinjectors and pen injectors; and continuous technological advancements that enhance safety, accuracy, and patient comfort. In addition, growing biological development, the shift toward home-based care, and greater focus on reducing hospital visits are further supporting market growth.

One of the major drivers of the pen and injector drug delivery devices market is the increasing prevalence of chronic diseases, along with the rapid growth of the geriatric population. Chronic conditions such as diabetes, cancer, cardiovascular diseases, and autoimmune disorders often require regular or long-term medication delivered through injections for fast and effective therapeutic action. According to the IDF's 2021 report, about 537 million people around the world had diabetes, which means roughly 1 in 10 people were affected. The number is expected to rise sharply, reaching 783 million people by 2045. As these diseases become more common in the world, the demand for reliable and easy-to-use injectable devices continues to increase. In addition, the aging population faces multiple health issues and typically requires frequent medical treatments, including injectable drugs. According to the recent population estimates and projections by UN DESA's Population Division, the number of people aged 60 and older is projected to reach 1.5 billion by 2050, representing about 1 in 6 people globally. This demographic shift is supporting the need for convenient, safe, and precise delivery systems that support both clinical use and home-based care, thereby contributing significantly to market growth.

Technological advancements in drug delivery systems are driving the growth of pen and injector drug delivery devices. Innovations have made injection devices safer, more efficient, and easier for patients to use. Features such as smart autoinjectors with digital monitoring, needle-free injection technologies, and improved safety mechanisms help ensure accurate dosing and reduce the risk of needle injuries. Advancements in materials and device design also enhance comfort and support self-use at home, which is becoming increasingly important for people managing chronic diseases. For instance, in October 2024, BD and Ypsomed announced a strategic collaboration to integrate BD's Neopak XtraFlow glass prefillable syringe, featuring a shorter 8 mm needle and a thinner-wall cannula, with Ypsomed's YpsoMate 2.25 autoinjector. This design makes high-viscosity biologic drugs easier to inject for patients self-administering at home, and the two-step injector is purpose-built to assist users with

limited grip or vision. Such technological improvements encourage adoption and support significant market growth.

Global Pen And Injector Drug Delivery Devices Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pen and injector drug delivery devices market report on the basis of product, therapeutic use, end use, and region.

• Product Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Injectors
  • GLP-1 Agonists
  • Hormone Therapies
  • Biologics
  • Others
• Pen
  • GLP-1 Agonists
  • Insulin
  • Hormone Therapies
  • Others
• Therapeutic Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Autoimmune Disorders
• Hormonal Disorders
• Oncology
• Obesity
• Diabetes Mellitus
• Others
• End Use Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• Hospitals
• Homecare Settings
• Others
• Regional Outlook (Volume, Units; Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Sweden
  • Denmark
• Asia
  • China
  • Japan
  • India
  • Thailand
  • South Korea
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Product
  • 1.2.2. Drug Type
  • 1.2.3. Therapeutic Use
  • 1.2.4. End Use
• 1.3. Estimation and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Materials & Third-Party Perspectives
  • 1.5.4. Primary Research
• 1.6. Information or Data Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Validation
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
    • 1.8.1.1. Research Scope and Assumptions
    • 1.8.1.2. Research Methodology and Assumptions
  • 1.8.2. Volume Price Analysis
  • 1.8.3. CDMO Pen and Injector Drug Delivery Devices Market
• 1.9. List of Secondary Sources
• 1.10. List of Abbreviations
• 1.11. Objectives
  • 1.11.1. Objective 1
  • 1.11.2. Objective 2
  • 1.11.3. Objective 3

Chapter 2. Executive Summary

• 2.1. Market Snapshot (Regional)
• 2.2. Segment Snapshot (Product)
• 2.3. Segment Snapshot (Therapeutic Use)
• 2.4. Segment Snapshot (End Use)
• 2.5. Market Concentration

Chapter 3. Pen and Injector Drug Delivery Devices Market Variables and Trends Market Lineage Outlook

• 3.1. Market Dynamics
  • 3.1.1. Market Driver Impact Analysis
  • 3.1.2. Market Restraint Analysis
  • 3.1.3. Market Opportunity Analysis
• 3.2. Industry Analysis Tools
  • 3.2.1. Porter's Five Forces Analysis
  • 3.2.2. Macroeconomic Analysis
• 3.3. List of CDMO Manufacturers and Supplied Pen and Injector Drug Delivery Devices to Companies
• 3.4. List of In-House Manufacturers of Pen and Injector Drug Delivery Devices
• 3.5. Qualitative Insights on Potential Impact of New Injectables or Oral Drugs and Development of Multi-Dose Devices, by Region
  • 3.5.1. North America
  • 3.5.2. Europe
  • 3.5.3. Asia
• 3.6. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021-2033 (value in USD Billion and Volume in Units Sold)
  • 3.6.1. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021- 2033 (USD Billion)
  • 3.6.2. Global CDMO Pen and Injector Drug Delivery Devices Market, by Product, 2021- 2033 (Units)

Chapter 4. Pen and Injector Drug Delivery Devices Market: Product Analysis

• 4.1. Product Movement Analysis & Market Share, 2025 & 2033
• 4.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Product (USD Billion, Units)
• 4.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 4.3.1. Injectors
    • 4.3.1.1. Injectors Market, 2021 - 2033 (USD Billion, Units)
    • 4.3.1.2. GLP-1 Agonists
      • 4.3.1.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.1.3. Hormone Therapies
      • 4.3.1.3.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.1.4. Biologics
      • 4.3.1.4.1. Biologics Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.1.5. Others
      • 4.3.1.5.1. Others Market, 2021 to 2033 (USD Billion, Units)
  • 4.3.2. Pen
    • 4.3.2.1. Pens Market, 2021 - 2033 (USD Billion, Units)
    • 4.3.2.2. GLP-1 Agonists
      • 4.3.2.2.1. GLP-1 Agonists Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.2.3. Insulin
      • 4.3.2.3.1. Insulin Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.2.4. Hormone Therapies
      • 4.3.2.4.1. Hormone Therapies Market, 2021 to 2033 (USD Billion, Units)
    • 4.3.2.5. Others
      • 4.3.2.5.1. Other Market Estimates & Forecasts, 2021 to 2033 (USD Billion, Units)

Chapter 5. Pen and Injector Drug Delivery Devices Market: Therapeutic Use Estimates & Trend Analysis

• 5.1. Therapeutic Area Movement Analysis & Market Share, 2025 & 2033
• 5.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by Therapeutic Use (USD Billion, Units)
• 5.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 5.3.1. Autoimmune Disorders
    • 5.3.1.1. Autoimmune Disorders Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.2. Hormonal Disorders
    • 5.3.2.1. Hormonal Disorders Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.3. Oncology
    • 5.3.3.1. Oncology Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.4. Obesity
    • 5.3.4.1. Obesity Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.5. Diabetes Mellitus
    • 5.3.5.1. Diabetes Mellitus Market, 2021 to 2033 (USD Billion, Units)
  • 5.3.6. Others
    • 5.3.6.1. Others Market, 2021 to 2033 (USD Billion, Units)

Chapter 6. Pen and Injector Drug Delivery Devices Market: End Use Analysis

• 6.1. End Use Movement Analysis & Market Share, 2025 & 2033
• 6.2. Pen and Injector Drug Delivery Devices Market Estimates & Forecast, by End Use (USD Billion, Units)
• 6.3. Market Size & Forecasts and Trend Analysis, 2021 to 2033
  • 6.3.1. Hospitals
    • 6.3.1.1. Hospitals Market, 2021 to 2033 (USD Billion, Units)
  • 6.3.2. Homecare Settings
    • 6.3.2.1. Homecare Settings Market, 2021 to 2033 (USD Billion, Units)
  • 6.3.3. Others
    • 6.3.3.1. Others Market, 2021 to 2033 (USD Billion, Units)

Chapter 7. Pen and Injector Drug Delivery Devices Market: Regional Estimates & Trend Analysis

• 7.1. Pen and Injector Drug Delivery Devices Market: Regional Outlook
• 7.2. North America
  • 7.2.1. North America Pen and Injector Drug Delivery Devices Market estimates and forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.2.2. U.S.
    • 7.2.2.1. Competitive Scenario
    • 7.2.2.2. Regulatory framework
    • 7.2.2.3. Reimbursement Structure
    • 7.2.2.4. U.S. Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.2.3. Canada
    • 7.2.3.1. Competitive Scenario
    • 7.2.3.2. Regulatory framework
    • 7.2.3.3. Reimbursement Structure
    • 7.2.3.4. Canada Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.2.4. Mexico
    • 7.2.4.1. Competitive Scenario
    • 7.2.4.2. Regulatory framework
    • 7.2.4.3. Reimbursement Structure
    • 7.2.4.4. Mexico Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
• 7.3. Europe
  • 7.3.1. Europe Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.2. UK
    • 7.3.2.1. Competitive Scenario
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Reimbursement Structure
    • 7.3.2.4. UK Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.3. Germany
    • 7.3.3.1. Competitive Scenario
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Reimbursement Structure
    • 7.3.3.4. Germany Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.4. France
    • 7.3.4.1. Competitive Scenario
    • 7.3.4.2. Regulatory framework
    • 7.3.4.3. Reimbursement Structure
    • 7.3.4.4. France Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.5. Italy
    • 7.3.5.1. Competitive Scenario
    • 7.3.5.2. Regulatory framework
    • 7.3.5.3. Reimbursement Structure
    • 7.3.5.4. Italy Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.6. Spain
    • 7.3.6.1. Competitive Scenario
    • 7.3.6.2. Regulatory framework
    • 7.3.6.3. Reimbursement Structure
    • 7.3.6.4. Spain Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.7. Norway
    • 7.3.7.1. Competitive Scenario
    • 7.3.7.2. Regulatory framework
    • 7.3.7.3. Reimbursement Structure
    • 7.3.7.4. Norway Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.8. Sweden
    • 7.3.8.1. Competitive Scenario
    • 7.3.8.2. Regulatory framework
    • 7.3.8.3. Reimbursement Structure
    • 7.3.8.4. Sweden Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.3.9. Denmark
    • 7.3.9.1. Competitive Scenario
    • 7.3.9.2. Regulatory framework
    • 7.3.9.3. Reimbursement Structure
    • 7.3.9.4. Denmark Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
• 7.4. Asia
  • 7.4.1. Asia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.2. China
    • 7.4.2.1. Competitive Scenario
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Reimbursement Structure
    • 7.4.2.4. China Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.3. Japan
    • 7.4.3.1. Competitive Scenario
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Reimbursement Structure
    • 7.4.3.4. Japan Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.4. India
    • 7.4.4.1. Competitive Scenario
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Reimbursement Structure
    • 7.4.4.4. India Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.5. Thailand
    • 7.4.5.1. Competitive Scenario
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Reimbursement Structure
    • 7.4.5.4. Thailand Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.6. South Korea
    • 7.4.6.1. Competitive Scenario
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Reimbursement Structure
    • 7.4.6.4. South Korea Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.7. Saudi Arabia
    • 7.4.7.1. Competitive Scenario
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Reimbursement Structure
    • 7.4.7.4. Saudi Arabia Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.8. UAE
    • 7.4.8.1. Competitive Scenario
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Reimbursement Structure
    • 7.4.8.4. UAE Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)
  • 7.4.9. Kuwait
    • 7.4.9.1. Competitive Scenario
    • 7.4.9.2. Regulatory framework
    • 7.4.9.3. Reimbursement Structure
    • 7.4.9.4. Kuwait Pen and Injector Drug Delivery Devices Market Estimates and Forecasts, 2021 - 2033 (USD Billion, Units)

Chapter 8. Pen and Injector Drug Delivery Devices Market: Competitive Analysis

• 8.1. Company Categorization
• 8.2. Participant's Overview
• 8.3. Financial Performance
• 8.4. Product Offerings
• 8.5. Company Market Position Analysis
• 8.6. Company Market Share Analysis, 2024 (%)
• 8.7. Strategy Mapping
  • 8.7.1. Product Launches & Approvals
  • 8.7.2. Partnerships & Collaborations
  • 8.7.3. Mergers & Acquisitions
  • 8.7.4. Expansions
  • 8.7.5. Others
• 8.8. Company Profiles
  • 8.8.1. Novo Nordisk A/S
    • 8.8.1.1. Company Overview
    • 8.8.1.2. Financial Performance
    • 8.8.1.3. Product Benchmarking
    • 8.8.1.4. Strategic Initiatives
  • 8.8.2. Sanofi
    • 8.8.2.1. Company Overview
    • 8.8.2.2. Financial Performance
    • 8.8.2.3. Product Benchmarking
    • 8.8.2.4. Strategic Initiatives
  • 8.8.3. Eli Lilly and Company
    • 8.8.3.1. Company Overview
    • 8.8.3.2. Financial Performance
    • 8.8.3.3. Product Benchmarking
    • 8.8.3.4. Strategic Initiatives
  • 8.8.4. AstraZeneca plc
    • 8.8.4.1. Company Overview
    • 8.8.4.2. Financial Performance
    • 8.8.4.3. Product Benchmarking
    • 8.8.4.4. Strategic Initiatives
  • 8.8.5. Pfizer, Inc.
    • 8.8.5.1. Company Overview
    • 8.8.5.2. Financial Performance
    • 8.8.5.3. Product Benchmarking
    • 8.8.5.4. Strategic Initiatives
  • 8.8.6. Merck KGaA
    • 8.8.6.1. Company Overview
    • 8.8.6.2. Financial Performance
    • 8.8.6.3. Product Benchmarking
    • 8.8.6.4. Strategic Initiatives
  • 8.8.7. Teva Pharmaceuticals
    • 8.8.7.1. Company Overview
    • 8.8.7.2. Financial Performance
    • 8.8.7.3. Product Benchmarking
    • 8.8.7.4. Strategic Initiatives
  • 8.8.8. Amgen, Inc.
    • 8.8.8.1. Company Overview
    • 8.8.8.2. Financial Performance
    • 8.8.8.3. Product Benchmarking
    • 8.8.8.4. Strategic Initiatives
  • 8.8.9. Ferring Pharmaceuticals
    • 8.8.9.1. Company Overview
    • 8.8.9.2. Financial Performance
    • 8.8.9.3. Product Benchmarking
    • 8.8.9.4. Strategic Initiatives
  • 8.8.10. AbbVie, Inc.
    • 8.8.10.1. Company Overview
    • 8.8.10.2. Financial Performance
    • 8.8.10.3. Product Benchmarking
    • 8.8.10.4. Strategic Initiatives

관련자료